Integrating nonpharmacologic interventions with pharmacologic management of lung respiratory distress symptoms is essential, according to Shanada Monestime, PharmD, the director of community engaged research with the patient advocacy group GO2 for Lung Cancer.
An older study showed that respiratory distress symptom intervention (RDSI) appears beneficial in improving dyspnea, cough and fatigue—the “respiratory distress symptom cluster” in patients with lung cancer. These three